
    
      This is an open-label, multicenter, Phase 2/3 study to evaluate the efficacy and safety of
      the combination of ublituximab + umbralisib + venetoclax (U2-V) compared to the combination
      of ublituximab + umbralisib (U2) in patients with either treatment na√Øve or previously
      treated CLL
    
  